Presenter: Dr. Del Dorscheid, University of British Columbia, Vancouver, BC
Moderator: Dr. Celine Bergeron, University of British Columbia, Vancouver, BC
The use of FeNO to monitor and/or assess “allergic inflammation” in the asthmatic population has not been fully embraced by respiratory practitioners nor supported by the consensus guidelines. Much of this was contributed to by variations in technology of the devices, variability in the results when applied to the entire population of “asthmatics” and a lack of translatable knowledge regarding whom would this benefit with respect to clinical outcomes. With a broader range of available therapeutic options the use of FeNO to identify personalized treatment plans needs to be revisited.
Learning Objectives
At the end of this presentation, attendees will be able to:
- Discuss the most up-to-date scientific and clinical evidence supporting the use of fractional exhaled nitric oxide (FeNO) as a biomarker to manage asthma and
- Debate its utility in Canadian practice with the introduction of biologics.
CanMEDs Competencies Addressed:
Health Advocate, Leader, Medical Expert, Professional, Scholar
This session is co-developed by the Canadian Thoracic Society and Sanofi Genzyme and is planned to achieve scientific integrity, objectivity and balance.
